198 related articles for article (PubMed ID: 31767949)
1. Molecular Dynamics Simulation reveals the mechanism by which the Influenza Cap-dependent Endonuclease acquires resistance against Baloxavir marboxil.
Yoshino R; Yasuo N; Sekijima M
Sci Rep; 2019 Nov; 9(1):17464. PubMed ID: 31767949
[TBL] [Abstract][Full Text] [Related]
2. In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit.
Noshi T; Kitano M; Taniguchi K; Yamamoto A; Omoto S; Baba K; Hashimoto T; Ishida K; Kushima Y; Hattori K; Kawai M; Yoshida R; Kobayashi M; Yoshinaga T; Sato A; Okamatsu M; Sakoda Y; Kida H; Shishido T; Naito A
Antiviral Res; 2018 Dec; 160():109-117. PubMed ID: 30316915
[TBL] [Abstract][Full Text] [Related]
3. Impact of the Baloxavir-Resistant Polymerase Acid I38T Substitution on the Fitness of Contemporary Influenza A(H1N1)pdm09 and A(H3N2) Strains.
Checkmahomed L; M'hamdi Z; Carbonneau J; Venable MC; Baz M; Abed Y; Boivin G
J Infect Dis; 2020 Jan; 221(1):63-70. PubMed ID: 31419295
[TBL] [Abstract][Full Text] [Related]
4. Influenza A and B viruses with reduced baloxavir susceptibility display attenuated in vitro fitness but retain ferret transmissibility.
Jones JC; Pascua PNQ; Fabrizio TP; Marathe BM; Seiler P; Barman S; Webby RJ; Webster RG; Govorkova EA
Proc Natl Acad Sci U S A; 2020 Apr; 117(15):8593-8601. PubMed ID: 32217734
[TBL] [Abstract][Full Text] [Related]
5. The impact of PA/I38 substitutions and PA polymorphisms on the susceptibility of zoonotic influenza A viruses to baloxavir.
Taniguchi K; Noshi T; Omoto S; Sato A; Shishido T; Matsuno K; Okamatsu M; Krauss S; Webby RJ; Sakoda Y; Kida H
Arch Virol; 2024 Jan; 169(2):29. PubMed ID: 38216710
[TBL] [Abstract][Full Text] [Related]
6. Baloxavir marboxil susceptibility of influenza viruses from the Asia-Pacific, 2012-2018.
Koszalka P; Tilmanis D; Roe M; Vijaykrishna D; Hurt AC
Antiviral Res; 2019 Apr; 164():91-96. PubMed ID: 30771405
[TBL] [Abstract][Full Text] [Related]
7. Influenza A virus polymerase acidic protein E23G/K substitutions weaken key baloxavir drug-binding contacts with minimal impact on replication and transmission.
Jones JC; Zagribelnyy B; Pascua PNQ; Bezrukov DS; Barman S; Okda F; Webby RJ; Ivanenkov YA; Govorkova EA
PLoS Pathog; 2022 Jul; 18(7):e1010698. PubMed ID: 35830486
[TBL] [Abstract][Full Text] [Related]
8. Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil.
Omoto S; Speranzini V; Hashimoto T; Noshi T; Yamaguchi H; Kawai M; Kawaguchi K; Uehara T; Shishido T; Naito A; Cusack S
Sci Rep; 2018 Jun; 8(1):9633. PubMed ID: 29941893
[TBL] [Abstract][Full Text] [Related]
9. Assessing baloxavir susceptibility of influenza viruses circulating in the United States during the 2016/17 and 2017/18 seasons.
Gubareva LV; Mishin VP; Patel MC; Chesnokov A; Nguyen HT; De La Cruz J; Spencer S; Campbell AP; Sinner M; Reid H; Garten R; Katz JM; Fry AM; Barnes J; Wentworth DE
Euro Surveill; 2019 Jan; 24(3):. PubMed ID: 30670144
[TBL] [Abstract][Full Text] [Related]
10. PA-E18G substitution in influenza A virus confers resistance to ZX-7101, a cap-dependent endonuclease inhibitor.
Luo D; Ye Q; Li RT; Zhou HY; Guo JJ; Zhao SQ; Zhang S; Jiang T; Deng YQ; Qin CF
Virol Sin; 2023 Aug; 38(4):559-567. PubMed ID: 37290559
[TBL] [Abstract][Full Text] [Related]
11. The active form of the influenza cap-snatching endonuclease inhibitor baloxavir marboxil is a tight binding inhibitor.
Todd B; Tchesnokov EP; Götte M
J Biol Chem; 2021; 296():100486. PubMed ID: 33647314
[TBL] [Abstract][Full Text] [Related]
12. Mutated influenza A virus exhibiting reduced susceptibility to baloxavir marboxil from an experimentally infected horse.
Nemoto M; Tamura N; Bannai H; Tsujimura K; Kokado H; Ohta M; Yamanaka T
J Gen Virol; 2019 Nov; 100(11):1471-1477. PubMed ID: 31526451
[TBL] [Abstract][Full Text] [Related]
13. Characterization of contemporary influenza B recombinant viruses harboring mutations of reduced susceptibility to baloxavir marboxil, in vitro and in mice.
Abed Y; Fage C; Checkmahomed L; Venable MC; Boivin G
Antiviral Res; 2020 Jul; 179():104807. PubMed ID: 32343991
[TBL] [Abstract][Full Text] [Related]
14. Rapid detection of an I38T amino acid substitution in influenza polymerase acidic subunit associated with reduced susceptibility to baloxavir marboxil.
Nakauchi M; Takashita E; Fujisaki S; Shirakura M; Ogawa R; Morita H; Miura H; Saito S; Watanabe S; Odagiri T; Kageyama T
Influenza Other Respir Viruses; 2020 Jul; 14(4):436-443. PubMed ID: 32064779
[TBL] [Abstract][Full Text] [Related]
15. Baloxavir marboxil, a novel cap-dependent endonuclease inhibitor potently suppresses influenza virus replication and represents therapeutic effects in both immunocompetent and immunocompromised mouse models.
Fukao K; Ando Y; Noshi T; Kitano M; Noda T; Kawai M; Yoshida R; Sato A; Shishido T; Naito A
PLoS One; 2019; 14(5):e0217307. PubMed ID: 31107922
[TBL] [Abstract][Full Text] [Related]
16. Influenza A variants with reduced susceptibility to baloxavir isolated from Japanese patients are fit and transmit through respiratory droplets.
Imai M; Yamashita M; Sakai-Tagawa Y; Iwatsuki-Horimoto K; Kiso M; Murakami J; Yasuhara A; Takada K; Ito M; Nakajima N; Takahashi K; Lopes TJS; Dutta J; Khan Z; Kriti D; van Bakel H; Tokita A; Hagiwara H; Izumida N; Kuroki H; Nishino T; Wada N; Koga M; Adachi E; Jubishi D; Hasegawa H; Kawaoka Y
Nat Microbiol; 2020 Jan; 5(1):27-33. PubMed ID: 31768027
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of avian-origin influenza A(H7N9) virus by the novel cap-dependent endonuclease inhibitor baloxavir marboxil.
Taniguchi K; Ando Y; Nobori H; Toba S; Noshi T; Kobayashi M; Kawai M; Yoshida R; Sato A; Shishido T; Naito A; Matsuno K; Okamatsu M; Sakoda Y; Kida H
Sci Rep; 2019 Mar; 9(1):3466. PubMed ID: 30837531
[TBL] [Abstract][Full Text] [Related]
18. Discovery of a Macrocyclic Influenza Cap-Dependent Endonuclease Inhibitor.
Feng J; Guo F; Li P; Zhang J; Jiang K; Zhu Z; Yin S; Lin X; Lin F; Xiao F; Xue X; He H; Chen S
J Med Chem; 2024 Feb; 67(4):2570-2583. PubMed ID: 38301207
[TBL] [Abstract][Full Text] [Related]
19. Detection of influenza A(H3N2) viruses exhibiting reduced susceptibility to the novel cap-dependent endonuclease inhibitor baloxavir in Japan, December 2018.
Takashita E; Kawakami C; Morita H; Ogawa R; Fujisaki S; Shirakura M; Miura H; Nakamura K; Kishida N; Kuwahara T; Mitamura K; Abe T; Ichikawa M; Yamazaki M; Watanabe S; Odagiri T;
Euro Surveill; 2019 Jan; 24(3):. PubMed ID: 30670142
[TBL] [Abstract][Full Text] [Related]
20. Influenza A virus polymerase acidic protein E23R substitution is a marker of reduced susceptibility to baloxavir.
Jones JC; Rovito SW; Penaflor MK; Webby RJ; Govorkova EA
Antiviral Res; 2022 Aug; 204():105369. PubMed ID: 35738347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
